查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1968547

Guillain-Barré二氏症候群诊断市场 - 全球产业规模、份额、趋势、机会、预测：按检测方法、最终用途、地区和竞争对手划分，2021-2031年

Guillain-Barre Syndrome Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test, By End-use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球Guillain-Barré二氏症候群诊断市场预计将从 2025 年的 1.6101 亿美元成长到 2031 年的 1.8552 亿美元，复合年增长率为 2.39%。

该市场涵盖了用于识别这种影响週边神经系统的急性自体免疫疾病所需的专业医学调查方法，例如脑脊髓液分析、肌电图和神经传导研究。推动该市场成长的关键因素包括兹卡病毒和曲状桿菌菌等领先感染在全球范围内的感染疾病率不断上升，以及易患自体免疫併发症的老龄人口不断增长。此外，早期疗育对于预防永久性神经损伤的重要性日益凸显，也显着推动了全球对精准诊断解决方案的需求成长。

市场概览
预测期 2027-2031
市场规模：2025年 161,010,000 美元
市场规模：2031年 1.8552亿美元
复合年增长率：2026-2031年 2.39%
成长最快的细分市场 腰椎穿刺
最大的市场 北美洲

儘管有这种需求，但由于神经系统专科手术高成本以及发展中地区缺乏熟练的专业人员等因素，市场面临许多障碍。这些因素常常导致误诊，而诊断差距加剧了疾病带来的社会经济负担。例如，根据格林-Guillain-Barré二氏症候群患者的就业状况因疾病而发生变化，这凸显了诊断延迟或不准确对患者生活和医疗保健系统造成的严重长期影响。

市场驱动因素

与Guillain-Barré二氏症候群)相关的感染疾病不断增加，是推动市场扩张的主要因素。随着病毒病原体和病毒感染后併发症引发自体免疫反应的病例增多，临床上对利用肌电图和腰椎穿刺进行快速鑑别诊断的需求日益增长。免疫因素与神经系统预后之间的相关性对于满足此诊断需求至关重要，因为临床医生需要将 GBS 与其他神经病变分开来，以便启动适当的治疗。例如，感染疾病研究与政策中心在 2024 年 2 月发布的报告《顾问讨论呼吸道合胞病毒疫苗接种后的格林-巴利病例》中指出，联邦卫生部门审查了 23 例在呼吸道融合细胞病毒疫苗接种后确诊的格林-巴利病例，强调需要加强诊断警惕性以排除其他病因。

同时，基于新型生物标记的诊断测试的开发正在透过实现精准医疗和提高预后准确性来变革该领域。这些先进的测试使临床医生能够更好地对患者进行分类，从而为新兴的补体抑制疗法做好准备，减少对排除性诊断的依赖，并提高康復率。 Annexon Biosciences 在 2024 年 6 月发布的新闻稿中证实了这种方法的有效性，该新闻稿介绍了一项 III 期临床试验，试验中，根据特定补体基准值进行治疗的患者，其缓解率比安慰剂组提高了 2.4 倍。这些临床成功正在推动对诊断生态系统的更广泛投资，Annexon Biosciences 在 2024 年筹集了 1.25 亿美元的资金，用于支持这些神经系统诊断和治疗创新成果的商业化，证明了这一点。

市场挑战

高成本，加上发展中地区熟练专科医生的短缺，为全球Guillain-Barré二氏症候群诊断市场带来了重大挑战。肌电图和神经传导检查等先进诊断技术需要昂贵的医疗设备和训练有素、能够准确解读复杂数据的神经科。在许多新兴经济体，医疗机构往往缺乏投资这些技术或维持专业人员所需的预算，导致诊断基础设施有显着差异。这阻碍了这些检测方案的广泛应用，并限制了市场向未开发地区的拓展。

此外，个人所承担的经济负担直接抑制了对诊断服务的需求。当患者面临高昂的检测费用时，他们往往会延迟或避免就医，导致检测数量减少，诊断机构的收入下降。近期疾病相关自付费用的数据也印证了这项经济负担。根据格林巴利症候群/慢性发炎性脱髓鞘多发性神经病变基金会（GBS/CIDP Foundation International）预测，到2025年，约有20%的患者每年将面临超过5,000美元的自付费用。如此沉重的经济负担阻碍了早期准确诊断，减缓了市场发展势头，并阻碍了全球先进诊断工具的普及应用。

市场趋势

将人工智慧 (AI) 应用于神经传导分析，透过自动化分析复杂的肌电图波形，正在革新格林巴利症候群 (GBS) 的诊断。这种整合消除了报告中的差异，并提高了对疾病早期阶段特征性细微去髓鞘化模式的检测准确性。以色列理工学院 (Technion Israel Institute of Technology) 于 2025 年 6 月发表的题为《主导智能体的 AI 神经传导研究和肌电图解读与报告》的报告重点强调了这些系统的临床有效性。该报告详细介绍了一个多智能体 AI 框架，该框架在检测异常方面实现了 92.2% 的诊断准确率。这种自动化准确率对于在神经专科人才匮乏的地区实现诊断标准的标准化至关重要。

此外，将高解析度超音波整合到诊断通讯协定中，建立了一种与电生理检查互补的非侵入性方法。该技术能够可视化形态学变化，例如面积增大，这些变化通常可作为电生理异常的领先指标。透过识别神经根肿胀，超音波有助于鑑别格林-巴利症候群（GBS）和慢性发炎性脱髓鞘性多发性神经病变。近期证据支持了这个效用。根据美国国立卫生研究院（NIH）于2025年8月发表的题为「Guillain-Barré二氏症候群周围神经大小的超音波评估」的报告，超音波影像显示患者组腓总神经存在显着肥大，与对照组相比平均差异为2.09，表明结构成像提供了一种明确的生物标誌物，可作为功能性神经传导数据的补充。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：Guillain-Barré二氏症候群诊断的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依检查类型（腰椎穿刺、肌电图等）
    • 按应用领域（医院/诊所、诊断检查室、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美Guillain-Barré二氏症候群诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲Guillain-Barré二氏症候群诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区Guillain-Barré二氏症候群诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东与非洲Guillain-Barré二氏症候群诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲Guillain-Barré二氏症候群诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球Guillain-Barré二氏症候群诊断市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Cadwell Industries, Inc
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Medtronic plc
  • Bionen srl
  • Deymed Diagnostic sro
  • Neurosoft Ivanovo, Russia
  • Alpine Biomedicals Pvt Ltd.
  • EMS Handels Gesellschaft mbH
  • Rochester Electro-Medical, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 27713

The Global Guillain-Barre Syndrome Diagnostics Market is projected to expand from USD 161.01 Million in 2025 to USD 185.52 Million by 2031, registering a CAGR of 2.39%. This market involves specialized medical testing methodologies, such as cerebrospinal fluid analysis, electromyography, and nerve conduction studies, which are essential for identifying this acute autoimmune disorder impacting the peripheral nervous system. The primary drivers fueling this growth include the increasing global incidence of antecedent infections, such as the Zika virus and Campylobacter jejuni, as well as an aging population that is more prone to autoimmune complications. Additionally, the critical need for early intervention to prevent permanent nerve damage is significantly boosting the demand for precise diagnostic solutions worldwide.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 161.01 Million
Market Size 2031USD 185.52 Million
CAGR 2026-20312.39%
Fastest Growing SegmentLumbar Puncture
Largest MarketNorth America

Despite this demand, the market faces a substantial obstacle due to the high cost of specialized neurological procedures and a shortage of skilled professionals in developing regions, factors that frequently lead to misdiagnosis. This diagnostic gap exacerbates the socioeconomic burden of the disease. For instance, data from the GBS/CIDP Foundation International in 2024 indicated that 41% of Guillain-Barre Syndrome patients underwent employment changes as a result of the condition, highlighting the severe long-term consequences that delayed or inaccurate diagnosis can have on patient livelihoods and healthcare systems.

Market Driver

The rising prevalence of infectious diseases associated with the onset of Guillain-Barre Syndrome acts as a major catalyst for market expansion. As viral pathogens and post-viral complications increasingly trigger autoimmune responses, there is an intensified clinical need for rapid differential diagnosis using electromyography and lumbar puncture. This connection between immune triggers and neurological outcomes is vital for validating diagnostic demand, as clinicians must distinguish GBS from other neuropathies to begin timely treatment. For example, in a February 2024 report titled 'Advisers discuss GBS cases after RSV vaccines,' the Center for Infectious Disease Research and Policy noted that federal health officials reviewed 23 verified cases of Guillain-Barre Syndrome following respiratory syncytial virus vaccinations, emphasizing the need for heightened diagnostic vigilance to rule out other causes.

Simultaneously, the development of novel biomarker-based diagnostic assays is transforming the sector by enabling precision medicine and enhancing prognostic accuracy. These advanced testing methods allow clinicians to better categorize patients for emerging complement-inhibitor therapies, thereby reducing reliance on exclusion-based diagnosis and improving recovery rates. The effectiveness of this approach was demonstrated in a June 2024 press release by Annexon Biosciences regarding their Phase 3 Trial, where patients treated based on specific complement benchmarks showed a 2.4-fold improvement in remission outcomes compared to a placebo. Such clinical success is driving broader investment in the diagnostic ecosystem, as evidenced by Annexon Biosciences raising $125 million in 2024 to support the commercial rollout of these neuro-diagnostic and therapeutic innovations.

Market Challenge

The high cost of specialized neurological procedures combined with the scarcity of skilled professionals in developing regions presents significant barriers to the growth of the Global Guillain-Barre Syndrome Diagnostics Market. Advanced diagnostic techniques, such as electromyography and nerve conduction studies, require expensive medical equipment and highly trained neurologists to accurately interpret complex data. In many emerging economies, healthcare institutions often lack the capital to invest in such technologies or the budget to retain specialized staff, creating a substantial gap in diagnostic infrastructure that prevents the widespread adoption of these testing solutions and limits market expansion into untapped geographical regions.

Moreover, the economic burden placed on individuals directly suppresses the demand for diagnostic services. When patients face prohibitive costs for testing, they often delay or avoid seeking medical attention, resulting in lower testing volumes and reduced revenue for diagnostic providers. This financial strain is evident in recent data concerning the personal costs associated with the condition; according to the GBS/CIDP Foundation International, in 2025, nearly 20% of patients reported facing annual out-of-pocket costs exceeding $5,000. This high financial liability discourages early and accurate diagnosis, thereby stalling market momentum and hindering the overall global adoption of precise diagnostic tools.

Market Trends

The adoption of Artificial Intelligence for Nerve Conduction Analysis is transforming GBS diagnostics by automating the analysis of complex electromyography waveforms. This integration resolves variability in reporting and improves the detection of subtle demyelinating patterns that characterize the early stages of the disease. The clinical validity of these systems was highlighted in a June 2025 report by the Technion Israel Institute of Technology titled 'Agent-guided AI-powered interpretation and reporting of nerve conduction studies and EMG,' which detailed a multi-agent AI framework achieving a diagnostic accuracy of 92.2% for detecting abnormal tests. Such automated precision is essential for standardizing diagnostic criteria across regions where specialized neurological expertise is limited.

Furthermore, the integration of High-Resolution Nerve Ultrasound into diagnostic protocols is establishing a non-invasive supplement to electrophysiology. This modality allows practitioners to visualize morphological changes, such as cross-sectional area enlargement, which often precede electrophysiological abnormalities. By identifying nerve root swelling, ultrasound assists in distinguishing GBS from mimicking neuropathies like CIDP. This utility is supported by recent evidence; according to an August 2025 report by the National Institutes of Health titled 'Ultrasound assessment of peripheral nerve size in Guillain-Barre syndrome,' ultrasound imaging revealed significant peroneal nerve enlargement in patients with a Mean Difference of 2.09 compared to controls, proving that structural imaging provides a confirmatory biomarker that complements functional nerve conduction data.

Key Market Players

  • Cadwell Industries, Inc
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Medtronic plc
  • Bionen s.r.l.
  • Deymed Diagnostic s.r.o.
  • Neurosoft Ivanovo, Russia
  • Alpine Biomedicals Pvt Ltd.
  • EMS Handels Gesellschaft m.b.H.
  • Rochester Electro-Medical, Inc.

Report Scope

In this report, the Global Guillain-Barre Syndrome Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Guillain-Barre Syndrome Diagnostics Market, By Test

  • Lumbar Puncture
  • Electromyography
  • Others

Guillain-Barre Syndrome Diagnostics Market, By End-use

  • Hospitals And Clinics
  • Diagnostic Laboratories
  • Others

Guillain-Barre Syndrome Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Guillain-Barre Syndrome Diagnostics Market.

Available Customizations:

Global Guillain-Barre Syndrome Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Guillain-Barre Syndrome Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test (Lumbar Puncture, Electromyography, Others)
    • 5.2.2. By End-use (Hospitals And Clinics, Diagnostic Laboratories, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Guillain-Barre Syndrome Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test
    • 6.2.2. By End-use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Guillain-Barre Syndrome Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test
        • 6.3.1.2.2. By End-use
    • 6.3.2. Canada Guillain-Barre Syndrome Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test
        • 6.3.2.2.2. By End-use
    • 6.3.3. Mexico Guillain-Barre Syndrome Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test
        • 6.3.3.2.2. By End-use

7. Europe Guillain-Barre Syndrome Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test
    • 7.2.2. By End-use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test
        • 7.3.1.2.2. By End-use
    • 7.3.2. France Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test
        • 7.3.2.2.2. By End-use
    • 7.3.3. United Kingdom Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test
        • 7.3.3.2.2. By End-use
    • 7.3.4. Italy Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test
        • 7.3.4.2.2. By End-use
    • 7.3.5. Spain Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test
        • 7.3.5.2.2. By End-use

8. Asia Pacific Guillain-Barre Syndrome Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test
    • 8.2.2. By End-use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test
        • 8.3.1.2.2. By End-use
    • 8.3.2. India Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test
        • 8.3.2.2.2. By End-use
    • 8.3.3. Japan Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test
        • 8.3.3.2.2. By End-use
    • 8.3.4. South Korea Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test
        • 8.3.4.2.2. By End-use
    • 8.3.5. Australia Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test
        • 8.3.5.2.2. By End-use

9. Middle East & Africa Guillain-Barre Syndrome Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test
    • 9.2.2. By End-use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Guillain-Barre Syndrome Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test
        • 9.3.1.2.2. By End-use
    • 9.3.2. UAE Guillain-Barre Syndrome Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test
        • 9.3.2.2.2. By End-use
    • 9.3.3. South Africa Guillain-Barre Syndrome Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test
        • 9.3.3.2.2. By End-use

10. South America Guillain-Barre Syndrome Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test
    • 10.2.2. By End-use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Guillain-Barre Syndrome Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test
        • 10.3.1.2.2. By End-use
    • 10.3.2. Colombia Guillain-Barre Syndrome Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test
        • 10.3.2.2.2. By End-use
    • 10.3.3. Argentina Guillain-Barre Syndrome Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test
        • 10.3.3.2.2. By End-use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Guillain-Barre Syndrome Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Cadwell Industries, Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Natus Medical Incorporated
  • 15.3. Nihon Kohden Corporation
  • 15.4. Medtronic plc
  • 15.5. Bionen s.r.l.
  • 15.6. Deymed Diagnostic s.r.o.
  • 15.7. Neurosoft Ivanovo, Russia
  • 15.8. Alpine Biomedicals Pvt Ltd.
  • 15.9. EMS Handels Gesellschaft m.b.H.
  • 15.10. Rochester Electro-Medical, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer